Arcus Biosciences Stock Forecast
NYSE: RCUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 23.99 +0.67%
RCUS analyst consensus
Consensus (13 analysts)
strong_buy
Avg. price target
$39.91+67.48%
- Strong buy 0
- Buy 11
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Arcus Biosciences (2026-10-07), 11 rate the stock a buy or strong buy, 2 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $39.91, with a high estimate of $47.00 and a low estimate of $23.00. The average target implies upside of 67.5% from the current price of $23.83.
The spread between the highest and lowest targets is 104.3%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for RCUS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 11 | 85% |
| Hold | 2 | 15% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $23.00 | -3.48% |
| Average target | $39.91 | +67.48% |
| High target | $47.00 | +97.23% |